medigraphic.com

2011, Number 4

<< Back Next >>

Cir Cir 2011; 79 (4)

Identification of prognostic factors in pancreatic cancer

Ruiz-Tovar J, Martín-Pérez E, Fernández-Contreras ME, Reguero-Callejas ME, Gamallo-Amat… C

Language: Spanish
References: 36
Page: 338-348
PDF size: 648.95 Kb.


ABSTRACT

Background: Surgical resection is the only potentially curative treatment for pancreatic cancer, but it is associated with high complication rates. Outcome is poor, even in those resected cases. Identification of prognostic factors preoperatively may help to improve treatment of these patients, based on the expected response.
Methods: A retrospective study of clinical variables of 59 patients with histological diagnosis of pancreatic carcinoma at University Hospitals Ramon y Cajal and La Princesa (Madrid, Spain) between 1999 and 2003 was performed.
Results: We analyzed 59 patients (32 males and 27 females) with a mean age of 63.76 years. All patients were operated on, performing palliative surgery in 32% and tumor resection in 68%, including pancreaticoduodenectomy in 51% and distal pancreatectomy in 17%. Median overall survival was 14 months (range: 1-110 months). We observed that the presence of abdominal pain (p = 0.042) and back pain (p = 0.004) at diagnosis, palpation of abdominal mass at physical examination (p = 0.012), preoperative levels of hemoglobin ‹12 g/dl (p = 0.0006) and serum albumin ‹2.8 g/dl (p = 0.021), perineural infiltration (p = 0.025), lymph node affection (p = 0.004), stages II, III, and IV (p = 0.001), and presence of residual tumor (R+) (p = 0.008) are all associated with poor survival.
Conclusions: Abdominal and back pain, palpation of abdominal mass at physical examination, preoperative levels of hemoglobin ‹12 g/dl and serum albumin ‹2.8 g/dl, perineural infiltration, lymph node affection, stages II, III, and IV, and the presence of residual tumor are associated with poor outcome.


REFERENCES

  1. Gawron AJ, Gapstur SM, Fought AJ, Talamonti MS, Skinner HG. Sociodemographic and tumour characteristics associated with pancreatic cancer surgery in the United States. J Surg Oncol 2008;97:578-582.

  2. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.

  3. García-Borobia FJ, Jorba-Martín R, Fabregat-Prous J. Adenocarcinoma de páncreas y del área periampular. En: Parrilla-Paricio P, Landa-García JI, eds. Cirugía AEC. Manual de la Asociación Española de Cirujanos. Madrid: Médica Panamericana; 2005. pp. 73-584.

  4. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.

  5. Friess H, Ko CK, Kleeff J. Pancreaticoduodenectomy, distal pancreatectomy, segmental pancretectomy, total pancretectomy and transduodenal resection of the papilla of Vater. En: Blumgart LH, ed. Surgery of the Liver, Biliary Tract and Pancreas. Philadelphia: Saunders; 2007. pp. 877-903.

  6. Kelsen DP, Portenoy R, Thaler H, Tao Y, Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997;122:53-59.

  7. Ridder GJ, Klempnauer J. Back pain in patients with ductal pancreatic cancer. Its impact on resectability and prognosis after resection. Scand J Gastroenterol 1995;30:1216-1220.

  8. DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol 1999;10:140-142.

  9. Scholmerich J. Diagnosis of pancreatic cancer. En: Beger HG, Buchler M, Malfertheiner P, eds. Standards in Pancreatic Surgery. Berlin: Springer-Verlag; 1993. p. 578.

  10. Kim HJ, Kim MH, Myung SJ, Lim BC, Park ET, Yoo KS, et al. A new strategy for the application of CA 19-9 in the differentiation of pancreatobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999;94:1941-1946.

  11. Morganti AG, Forni F, Macchia G, Valentini V, Smaniotto D, Trodella L, et al. Chemoradiation of unresectable pancreatic carcinoma: impact of pre-treatment haemoglobin levels on patterns of failure. Strahlenther Onkol 2003;179:87-92.

  12. Schäfer U, Micke O, Müller SB, Schüller P, Willich N. Hemoglobin as an independent prognostic factor in the radiotherapy of head and neck tumors. Strahlenther Onkol 2003;179:527-534.

  13. Valencia-Julve J, Alonso-Orduña V, Esco-Barón R, López-Mata M, Méndez-Villamón A. Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Trans Oncol 2006;8:22-30.

  14. Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, et al. Importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999;86:1528-1536.

  15. Pollack A, Zagars GK, Dinney CP, Swanson DA, von Eschenbach AC. Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients. Cancer 1994;74:2819-2827.

  16. Reichel O, Panzer M, Wimmer C, Dühmke E, Kastenbauer E, Suckfüll M. Prognostic implications of haemoglobin levels before and after surgery as well as before and after chemotherapy for head and neck tumours. Eur Arch Otorhinolaryngol 2003;260:248-253.

  17. Kong AC, Mehta V, Le QT. Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 2000;48:919-922.

  18. Molls M, Stadler P, Becker A, Feldmann HJ, Dunst J. Relevance of oxygen in radiation oncology. Strahlenther Onkol 1998;174:13-16.

  19. Dunst J, Pigorsch S, Hansen G. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis? Strahlenther Onkol 1999;175:93-96.

  20. Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.

  21. Sweeney PJ, Nicolae D, Ignacio L, Chen L, Roach M 3rd, Wara W, et al. Effects of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial. Br J Cancer 1998;77:1996-2002.

  22. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 1999;134:36-42.

  23. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993;72:3091-3098.

  24. McMillan DC, Watson WS, O’Gorman P. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 2001;39:210-213.

  25. Siddiqui A, Heinzerling J, Livingston EH, Huerta S. Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg 2007;194:362-366.

  26. Schmid I, Schmitt M, Streiter M, Meilbeck R, Haas RJ, Stachel DK. Effects of soluble TNF receptor II (sTNF-RII), IL-1 receptor antagonist (IL-1ra), tumor load and hypermetabolism on malnutrition in children with acute leukaemia. Eur J Med Res 2005;10:457-461.

  27. House MG, Gönen M, Jarnagin WR, D’Angelica M, DeMatteo RP, Fong Y, et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007;11:1549-1555.

  28. Schward RE, Smith DD. Extent of lymph node retrieval and pancreatic cancer survival: information from a large US population database. Ann Surg Oncol 2006;13:1189-1200.

  29. Pawlik TM, Gleisner AL, Cameron JL, Winter JM, Assumpcao L, Lillemoe KD, et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-618.

  30. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-240.

  31. Slidell MB, Chang DC, Cameron JL, Wolfgang C, Herman JM, Schulick RD, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2007;15:165-174.

  32. Merkel S, Mansmann U, Meyer T, Papadopoulos T, Hohenberger W, Hermanek P. Confusion by frequent changes in staging of exocrine pancreatic carcinoma. Pancreas 2004;29:171-178.

  33. Garcea G, Dennison AR, Ong SL, Pattenden CJ, Neal CP, Sutton CD, et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of the pancreas. Eur J Surg Oncol 2007;33:892-897.

  34. Howard TJ, Krug JE, Yu J, Zyromski NJ, Schmidt CM, Jacobson LE, et al. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to longterm survival in pancreatic cancer. J Gastrointest Surg 2006;10:1338-1345.

  35. Ridwelski K, Meyer F, Schmidt U, Lippert H. Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection. Zentralbl Chir 2005;130:353-361.

  36. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004;91:586-594.




2020     |     www.medigraphic.com